LOS ANGELES, Feb. 26, 2019 – ImaginAb, Inc., a clinical stage immuno-oncology imaging company, announced today the appointment of Ian Wilson as Chief Executive Officer while Martyn Coombs steps down for family reasons, effective immediately. In addition, Tim Irish has joined ImaginAb’s Board of Directors as an independent non-executive Director and Jeffrey Evelhoch, Ph.D. has joined the Company’s Scientific Advisory Board.
Ian Wilson, CEO of ImaginAb said, “I am honored to take this leadership role at ImaginAb, and continue to build on the many successes we have achieved, most notably in the last two years. Our ImaginAb team extends a warm welcome to Tim and Jeff as they embark on their new Board roles. We look forward to leveraging their extensive experience within global pharmaceutical companies as we continue to expand our strategic relationships and our clinical programs.”
With over 25 years of experience in the commercial development of in vivo medical diagnostics and imaging medical devices, Ian originally joined ImaginAb in early 2018 as Chief Operations Officer, driving clinical execution and R&D. Prior to that, he was CEO and Chief Technology Officer of Edinburgh Molecular Imaging Ltd., leading the development of novel optical imaging agents. Ian has also held positions at Xstrahl Ltd., as CTO and COO, and numerous roles at GE Healthcare including Portfolio and Strategy Manager and Head of Biology.
“I am delighted to be joining the ImaginAb Board of Directors, as the team forges its exciting path towards developing much-needed tools that can measure CD8 T Cells in patients. This vital technology will aid the whole immuno-oncology area in patient selection and management and drive us toward improved outcomes,” said Mr. Tim Irish.
Tim Irish has worked in the life sciences industry for thirty years with a career spanning global health technology companies across Europe and North America, including GSK, GE and Philips. Between 2007 and 2015 Tim served on ten Boards, five as Chair, where he successfully executed two trade sales and raised significant equity financing, including an IPO. Since 2015 his governance portfolio covers Life Sciences and Healthcare, both public and private, including board roles as Senior Independent Director and Non-Executive Director at NICE, four European NED roles, and Professor of Practice at King’s College London’s School of Management and Business.
“ImaginAb’s application of precision imaging has the potential to increase our understanding of cancer immunology and may fundamentally change how cancer is treated,” said Jeff Evelhoch, Ph.D. “I am excited to work with the other esteemed members of the ImaginAb Scientific Advisory Board to help advance this novel technology.”
Jeff Evelhoch, Ph.D., is responsible for development and qualification of novel biomarkers, use of biomarkers to inform pipeline decisions and the development and deployment of companion diagnostics at Merck. Jeff joined Merck Research Laboratories in 2008 as Vice President and Head of Imaging and was named Vice President and Head of Translational Biomarkers in 2015. He joined Merck after four years at Amgen as Executive Director and Head of Imaging Sciences, which followed 2 years at Pfizer Global Research & Development and Pharmacia as Director of Structural Imaging.
ImaginAb, Inc. is an immuno-oncology imaging company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is also developing a pipeline for other targets in oncology. ImaginAb’s products have the potential to improve patient care and lower healthcare costs.
For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com.
SOURCE ImaginAb, Inc.